Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural uganda

Susan A. Adakun, Mark J. Siedner, Conrad Muzoora, Jessica E. Haberer, Alexander C. Tsai, Peter W. Hunt, Jeff N. Martin, David Bangsberg

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

We examined the association between CD4 cell count and adherence in a cohort of Ugandans initiating antiretrovirals (ARVs). Outcomes were (a) adherence < 90%; (b) any treatment interruptions . 72 hours; (c) number of treatment interruptions; and (d) HIV-RNA > 400 copies/μL. We fit regression models to estimate associations with our exposure of interest, baseline CD4 cell count ≥ 250 cells/μL (n = 60) vs > 250 cells/μL (n = 413). CD4 cell count ≥250 cells/μL was independently associated with increased odds and number of treatment interruptions and increased odds of persistent viremia. Interventions to support adherence in patients with higher CD4 cell counts should be considered as drug availability to this population increases.

Original languageEnglish (US)
Pages (from-to)317-321
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume62
Issue number3
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

Keywords

  • Adherence
  • Adherence monitoring
  • HIV/aids
  • MEMS
  • Test and treat
  • Uganda

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural uganda'. Together they form a unique fingerprint.

  • Cite this